Biosenic (STU:BT1) EPS (Basic) : €-0.18 (TTM As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Biosenic EPS (Basic)?

Biosenic's basic earnings per share (Basic EPS) for the six months ended in Jun. 2023 was €-0.17. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.18.

Biosenic's EPS (Diluted) for the six months ended in Jun. 2023 was €-0.17. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was €-0.18.

Biosenic's EPS without NRI for the six months ended in Jun. 2023 was €-0.07. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2023 was -0.08.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Biosenic EPS (Basic) Historical Data

The historical data trend for Biosenic's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosenic EPS (Basic) Chart

Biosenic Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EPS (Basic)

Get a 7-Day Free Trial

-1.87

-1.08

-1.02

-14.89

-0.02

Biosenic Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EPS (Basic)	Get a 7-Day Free Trial															-0.52	0.24	-7.49	-0.01	-0.17

Biosenic EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Biosenic's Basic EPS for the fiscal year that ended in Dec. 2022 is calculated as

Basic EPS (A: Dec. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.041	-	0)	/	120.132
	=	-0.02

Biosenic's Basic EPS for the quarter that ended in Jun. 2023 is calculated as

Basic EPS (Q: Jun. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-20.843	-	0)	/	124.496
	=	-0.17

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.18

Biosenic (STU:BT1) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Biosenic EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Biosenic's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosenic (STU:BT1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosenic (STU:BT1) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

BT1:Germany BIOS:Belgium

Address

Rue Granbonpre 11, Batiment H (bte 24), Mont-St-Guibert, Gosselies, BEL, 1435

Website

https://www.biosenic.com

Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.

Biosenic (STU:BT1) Headlines

No Headlines